Skip to main content
. 2018 Jan 30;14(1):e1006877. doi: 10.1371/journal.ppat.1006877

Fig 2. Secondary validation of the primary screen results to identify the most effective anti-SeV ISGs.

Fig 2

(A) The z-scores of all the ISG shRNAs based on their anti-SeV activities; all z-scores were normalized to that of shIRF9. (B) The z-scores of the top 25 primary hits that were used for secondary validation. (C) HeLa cells, stably expressing the shRNAs against specific ISGs (indicated above by the numbers, 1–25) were treated with IFN-β for 16 h, when the cells were infected with SeV and analyzed for SeV C protein by immunoblot at 16 hpi. (D) The secondary validated anti-SeV ISGs, their z-scores and known functions.